{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T02:02:54Z","timestamp":1784599374623,"version":"3.55.0"},"reference-count":18,"publisher":"ARAN Ediciones","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hipertensi\u00f3n y Riesgo Vascular"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.hipert.2024.02.007","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T09:27:37Z","timestamp":1710840457000},"page":"75-77","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Is proteinuria an important fact concerning the nephroprotective effect of renin-angiotensin system inhibitors?"],"prefix":"10.20960","volume":"41","author":[{"given":"J.M.","family":"Galceran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"8588","reference":[{"key":"10.1016\/j.hipert.2024.02.007_bib0095","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1001\/archinte.1997.00440420033005","article-title":"The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure","volume":"157","year":"1997","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.hipert.2024.02.007_bib0100","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","article-title":"Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure","volume":"42","author":"Chobanian","year":"2003","journal-title":"Hypertension"},{"issue":"Suppl. 1","key":"10.1016\/j.hipert.2024.02.007_bib0105","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification","volume":"39","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.hipert.2024.02.007_bib0110","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/00004872-200306000-00001","article-title":"2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension","volume":"21","year":"2003","journal-title":"J Hypertens"},{"key":"10.1016\/j.hipert.2024.02.007_bib0115","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/HJH.0b013e3281fc975a","article-title":"2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"25","author":"Mancia","year":"2007","journal-title":"J Hypertens"},{"key":"10.1016\/j.hipert.2024.02.007_bib0120","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.hipert.2024.02.007_bib0125","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/01.hjh.0000431740.32696.cc","article-title":"Task Force Members 2013 ESH\/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"31","author":"Mancia","year":"2013","journal-title":"J Hypertens"},{"key":"10.1016\/j.hipert.2024.02.007_bib0130","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1046\/j.1523-1755.2001.0600031131.x","article-title":"Angiotensin-converting enzyme inhibition and progression of renal disease proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease","volume":"60","author":"Jafar","year":"2001","journal-title":"Kidney Int"},{"issue":"Suppl. 3","key":"10.1016\/j.hipert.2024.02.007_bib0135","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1524-6175.2004.04065.x","article-title":"Implications of albuminuria on kidney disease progression","volume":"6","author":"Bakris","year":"2004","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.hipert.2024.02.007_bib0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-151-1-200907070-00122","article-title":"Effect of telmisartan on renal outcomes: a randomized trial","volume":"151","author":"Mann","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.hipert.2024.02.007_bib0145","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK Trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.hipert.2024.02.007_bib0150","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1161\/01.HYP.0000166746.04472.60","article-title":"Blood pressure control, drug therapy, and kidney disease","volume":"46","author":"Contreras","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.hipert.2024.02.007_bib0155","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1001\/archinte.165.8.936","article-title":"Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"165","author":"Rahman","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.hipert.2024.02.007_bib0160","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1681\/ASN.2006101081","article-title":"Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease","volume":"18","author":"Kent","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.hipert.2024.02.007_bib0165","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1681\/ASN.2006121372","article-title":"Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency","volume":"18","author":"Hou","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.hipert.2024.02.007_bib0170","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1097\/HJH.0b013e328277596e","article-title":"Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus","volume":"25","author":"Hollenberg","year":"2007","journal-title":"J Hypertens"},{"key":"10.1016\/j.hipert.2024.02.007_bib0175","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.hipert.2023.11.005","article-title":"Renin-angiotensin-aldosterone system blockers effect in chronic kidney disease progression in hypertensive elderly patients without proteinuria: PROERCAN trial","volume":"41","author":"Garc\u00eda-Prieto","year":"2024","journal-title":"Hipertens Riesgo Vasc"},{"key":"10.1016\/j.hipert.2024.02.007_bib0180","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S2213-8587(23)00321-2","article-title":"Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney, trial","volume":"12","year":"2024","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Hipertensi\u00f3n y Riesgo Vascular"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1889183724000333?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1889183724000333?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T01:15:38Z","timestamp":1784596538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1889183724000333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S1889183724000333"],"URL":"https:\/\/doi.org\/10.1016\/j.hipert.2024.02.007","relation":{},"ISSN":["1889-1837"],"issn-type":[{"value":"1889-1837","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is proteinuria an important fact concerning the nephroprotective effect of renin-angiotensin system inhibitors?","name":"articletitle","label":"Article Title"},{"value":"Hipertensi\u00f3n y Riesgo Vascular","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hipert.2024.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 SEH-LELHA. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}